Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Northwest Biotherapeutics (NWBO) Other Non Operating Income (2016 - 2025)

Historic Other Non Operating Income for Northwest Biotherapeutics (NWBO) over the last 15 years, with Q3 2025 value amounting to -$12.5 million.

  • Northwest Biotherapeutics' Other Non Operating Income fell 8341.64% to -$12.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$31.7 million, marking a year-over-year decrease of 44475.4%. This contributed to the annual value of -$17.3 million for FY2024, which is 14354.82% down from last year.
  • According to the latest figures from Q3 2025, Northwest Biotherapeutics' Other Non Operating Income is -$12.5 million, which was down 8341.64% from -$4.5 million recorded in Q2 2025.
  • Northwest Biotherapeutics' Other Non Operating Income's 5-year high stood at $145.8 million during Q4 2021, with a 5-year trough of -$17.2 million in Q3 2022.
  • Moreover, its 5-year median value for Other Non Operating Income was -$2.6 million (2024), whereas its average is $8.3 million.
  • The largest annual percentage gain for Northwest Biotherapeutics' Other Non Operating Income in the last 5 years was 37657.86% (2024), contrasted with its biggest fall of 73218.88% (2024).
  • Northwest Biotherapeutics' Other Non Operating Income (Quarter) stood at $145.8 million in 2021, then plummeted by 106.94% to -$10.1 million in 2022, then soared by 111.51% to $1.2 million in 2023, then plummeted by 732.19% to -$7.4 million in 2024, then crashed by 69.84% to -$12.5 million in 2025.
  • Its last three reported values are -$12.5 million in Q3 2025, -$4.5 million for Q2 2025, and -$7.3 million during Q1 2025.